October 24, 2025 09:00 AM PST
(PenniesToSave.com) – As the government shutdown continues, essential federal workers and military personnel remain unpaid while members of Congress still collect salaries and campaign donations. The optics have stirred outrage among taxpayers, particularly as records show pharmaceutical companies have poured millions into congressional campaigns. This investigation follows the money trail, connects it to recent legislative behavior, and explores how the shutdown’s effects are rippling through American households.
Quick Links
- What happened in the Senate and House on federal worker pay?
- Who are some of the key lawmakers receiving large-scale contributions from the pharma industry?
- Is it plausible that these contributions influenced the vote on worker pay?
- Why does this matter financially to average American households?
- What about the alternative funding sources and the threats of lawsuit from Congress?
- What can readers do and what should Congress do?
What happened in the Senate and House on federal worker pay?
The Senate blocked two separate bills designed to protect federal employee pay during the government shutdown. Senator Ron Johnson of Wisconsin introduced legislation to guarantee pay for “excepted” workers and military members. It failed to reach the 60-vote threshold, falling 54 to 45. Democrats offered a broader measure to cover all federal employees, including furloughed workers, but that effort also failed to advance.
In the House, Speaker Mike Johnson refused to consider a standalone bill guaranteeing military pay, arguing that worker pay should be addressed within a broader funding resolution. Consequently, hundreds of thousands of federal employees continue to work without pay, while others are furloughed. The human cost is immediate: families are struggling with missed rent, mortgage payments, and credit obligations. Local economies near federal facilities are already experiencing downturns.
These events underscore a central issue, partisan gridlock directly translates into economic harm for working families. When Washington fails to act, it is everyday Americans, not politicians, who bear the consequences.
Who are some of the key lawmakers receiving large-scale contributions from the pharma industry?
According to OpenSecrets, the pharmaceutical and health products industry is among the top spenders in federal politics, contributing approximately $86 million during the 2023–2024 election cycle. This money came from political action committees (PACs) and individuals associated with drug and healthcare companies, not corporate treasuries. The pattern of contributions spans both parties, illustrating how widespread the influence has become.
Below is a breakdown of major recipients among current senators and representatives:
| Lawmaker | Chamber | State | Total from Pharma/Health Products (2023–2024) |
|---|---|---|---|
| Bob Casey (D-PA) | Senate | Pennsylvania | $624,574 |
| Jon Tester (D-MT) | Senate | Montana | $576,423 |
| Sherrod Brown (D-OH) | Senate | Ohio | $478,109 |
| Scott Peters (D-CA) | House | California | $351,378 |
| Jacky Rosen (D-NV) | Senate | Nevada | $341,471 |
| Lisa Blunt Rochester (D-DE) | House | Delaware | $331,402 |
| Ruben Gallego (D-AZ) | House | Arizona | $326,292 |
| Colin Allred (D-TX) | House | Texas | $320,535 |
| Frank Pallone Jr. (D-NJ) | House | New Jersey | $301,880 |
The largest pharmaceutical-affiliated PACs donating in this period include companies such as Amgen, AbbVie, Pfizer, Merck, and Johnson & Johnson, with contributions often exceeding half a million dollars per cycle. While these donations are legally permissible, they raise legitimate questions about influence. Voters increasingly ask whether corporate financial support has become a quiet but decisive factor in determining legislative outcomes.
Is it plausible that these contributions influenced the vote on worker pay?
No direct evidence exists proving pharmaceutical companies paid lawmakers to block worker pay during the shutdown. Nonetheless, the coincidence between large industry donations and political outcomes favorable to the status quo creates a perception of undue influence. This is especially concerning given the pharmaceutical industry’s reputation for precision targeting of legislators on key committees, including those overseeing healthcare and budget policy.
Critics argue that this money effectively buys access, helping industries maintain policies that preserve profit margins. Lawmakers and industry defenders insist donations support candidates whose values already align with the donors’ interests. While such reasoning may be legally sound, it does little to reassure taxpayers. The appearance of influence alone undermines public confidence.
For families watching bills mount during the shutdown, the problem is less about campaign finance law and more about fairness. The disconnect between those in power and those living paycheck to paycheck has rarely been more visible.
How Pharmaceutical Companies Profit When Obamacare Subsidies Continue
Pharmaceutical companies also benefit from ongoing federal subsidies tied to the Affordable Care Act (ACA). These subsidies also act as an indirect public funding mechanism. The government provides billions to insurers to reduce premiums, and those insurers use the money to pay for drugs from pharmaceutical companies. This ensures a consistent demand for medications regardless of economic downturns. Moreover, the ACA did not authorize the federal government to negotiate drug prices directly for these plans, allowing pharmaceutical companies to maintain higher prices. This lack of price controls means that taxpayers effectively subsidize both coverage and inflated drug costs.
The law’s requirement to cover preexisting conditions further guarantees revenue for chronic illness medications such as insulin, hypertension treatments, and biologics. These recurring prescriptions are among the most profitable in the industry.
Investors benefit as well. Federal subsidies provide market stability, ensuring steady revenue streams for companies like Pfizer, Merck, and Eli Lilly. With subsidies in place, stock prices remain secure, and market analysts project predictable long-term profits.
In short, continued Obamacare subsidies mean more paying customers, protected pricing, and sustained profits. That reality gives pharmaceutical companies strong incentive to support policies and lawmakers who ensure the ACA’s longevity and resist reforms that might reduce drug prices or change the structure of federal health funding.
Why does this matter financially to average American households?
The shutdown’s economic toll stretches far beyond the Capitol. Federal employees unable to collect paychecks face growing debts, skipped payments, and financial uncertainty. This strain trickles down into surrounding communities as local stores, restaurants, and landlords see spending decline. Each missed paycheck represents thousands of dollars not circulating in local economies.
For American households, the financial pressure of a shutdown feels no different than a sudden layoff. Meanwhile, industries with strong lobbying presence, including pharmaceuticals, continue to report record profits. This contrast between working families and well-funded corporations highlights a deeper problem; political incentives appear disconnected from real-world economic pain.
From a conservative perspective, fiscal responsibility and accountability demand that Congress prioritize core obligations, such as ensuring essential workers are paid, before engaging in partisan disputes. For taxpayers, fairness requires that elected officials manage budgets efficiently while avoiding any appearance of favoritism toward donors.
What about the alternative funding sources and the threats of lawsuit from Congress?
Facing public outrage, the administration explored alternative ways to pay military personnel and essential workers using tariff revenue and other non-appropriated funds. Legal experts and members of Congress quickly warned that such actions might violate the Constitution’s power-of-the-purse clause, which reserves spending authority for Congress.
Several lawmakers signaled they would pursue legal action if the administration diverted these funds without authorization. Federal unions also threatened to sue, arguing that such measures would create uncertainty for workers and undermine appropriations laws. The resulting standoff intensified an already volatile situation.
This confrontation reveals a broader governance issue. While essential employees continue to work without pay, political leaders are focused on who holds the authority to disburse funds. Americans watching from the sidelines see little concern for their livelihoods, only for power struggles. Both parties claim to defend constitutional integrity, yet the outcome leaves workers unpaid and trust in government diminished.
What can readers do and what should Congress do?
Citizens can begin by reviewing the campaign contributions of their representatives using resources like the Federal Election Commission and OpenSecrets.org. These records expose the industries most involved in political giving and can inform voters ahead of future elections. Contacting lawmakers directly, either by phone or email, to demand explanations for votes impacting essential workers can help reinforce accountability.
Congress can strengthen trust by enforcing stricter disclosure laws, limiting industry donations to key committees, and passing legislation that permanently guarantees pay continuity for essential workers during shutdowns. Such reforms would protect both taxpayers and public servants from political gamesmanship.
For Americans concerned about the direction of the country, these steps are vital. A transparent and responsible government not only ensures public confidence but also safeguards the people who keep the nation running.
Final Thoughts
The ongoing shutdown has exposed a profound imbalance between political interests and public duty. Essential workers continue to perform their responsibilities without pay, while corporate donations flow freely into campaign coffers. Even if there is no direct evidence of quid pro quo, the optics suggest a political culture more responsive to donors than to citizens.
For households feeling the pinch of delayed paychecks and disrupted services, the stakes are deeply personal. A functioning democracy depends on the fair and transparent operation of government. That means ensuring the people who serve the nation are paid, and those elected to lead are held accountable for their financial and ethical choices.
Works Cited
Beggin, Riley, and Theodoric Meyer. “Senate Blocks Bills to Pay Federal Workers During Shutdown.” The Washington Post, 23 Oct. 2025, www.washingtonpost.com/business/2025/10/23/senate-blocks-bills-pay-federal-workers-during-shutdown/.
“Dueling Plans to Pay Feds On Time Fail in Senate, Though a Bipartisan Path Forward Appears.” GovExec, 23 Oct. 2025, www.govexec.com/pay-benefits/2025/10/dueling-plans-pay-feds-time-fail-senate-though-bipartisan-path-forward-appears/409026/.
Facher, Lev, and Rachel Cohrs Zhang. “No, Bernie Sanders and Elizabeth Warren Aren’t Top Recipients of Pharmaceutical Industry Donations.” STAT News, 3 Feb. 2025, www.statnews.com/2025/02/03/big-pharma-pac-contributions-bernie-sanders-elizabeth-warren-open-secrets-data/.
“Pharmaceuticals / Health Products Recipients – Top 20 Member Recipients of Money from Pharmaceuticals / Health Products, 1990–2024.” OpenSecrets, 2024, www.opensecrets.org/industries/summary?cycle=All&ind=H04&recipdetail=M&sortorder=U.
“Pharmaceuticals / Health Products Summary.” OpenSecrets, 2024, www.opensecrets.org/industries/indus?ind=H04.
“Pharmaceuticals / Health Products Top Contributors.” OpenSecrets, 2024, www.opensecrets.org/industries/contrib?cycle=2024&ind=H04.
“Essential Workers Left Unpaid After Senate Democrats Kill Pay Bill.” Fox News, 23 Oct. 2025, www.foxnews.com/politics/essential-workers-left-unpaid-after-senate-democrats-kill-pay-bill.
“Where Big Pharma’s Campaign Cash Is Flowing in This Election.” PharmaVoice, 2024, www.pharmavoice.com/news/big-pharma-campaign-election-pac-donations/731124.